Compare CELC & MUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CELC | MUR |
|---|---|---|
| Founded | 2011 | 1950 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.6B |
| IPO Year | 2017 | 1994 |
| Metric | CELC | MUR |
|---|---|---|
| Price | $88.82 | $38.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 14 |
| Target Price | ★ $112.56 | $34.36 |
| AVG Volume (30 Days) | ★ 1.6M | 1.6M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $2,718,823,000.00 |
| Revenue This Year | N/A | $9.45 |
| Revenue Next Year | $720.19 | $3.94 |
| P/E Ratio | ★ N/A | $104.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.54 | $21.86 |
| 52 Week High | $151.02 | $43.34 |
| Indicator | CELC | MUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 50.11 |
| Support Level | $83.77 | $35.55 |
| Resistance Level | $117.61 | $41.70 |
| Average True Range (ATR) | 7.68 | 1.40 |
| MACD | -3.25 | 0.14 |
| Stochastic Oscillator | 9.24 | 63.11 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.